S&P 500   3,750.43 (-0.87%)
DOW   29,952.91 (-1.06%)
QQQ   280.02 (-0.70%)
AAPL   145.60 (-0.55%)
MSFT   247.09 (-0.85%)
META   139.51 (+0.38%)
GOOGL   101.49 (+0.06%)
AMZN   120.27 (-0.56%)
TSLA   239.29 (-0.63%)
NVDA   131.52 (-0.43%)
NIO   14.89 (-7.17%)
BABA   84.55 (+0.19%)
AMD   68.20 (+0.38%)
T   15.38 (-3.45%)
MU   54.68 (-0.09%)
CGC   3.26 (+6.19%)
F   12.37 (-1.12%)
GE   66.00 (-2.14%)
DIS   100.08 (-0.71%)
AMC   7.22 (-1.50%)
PYPL   94.27 (+0.47%)
PFE   43.12 (-2.27%)
NFLX   240.58 (+1.63%)
S&P 500   3,750.43 (-0.87%)
DOW   29,952.91 (-1.06%)
QQQ   280.02 (-0.70%)
AAPL   145.60 (-0.55%)
MSFT   247.09 (-0.85%)
META   139.51 (+0.38%)
GOOGL   101.49 (+0.06%)
AMZN   120.27 (-0.56%)
TSLA   239.29 (-0.63%)
NVDA   131.52 (-0.43%)
NIO   14.89 (-7.17%)
BABA   84.55 (+0.19%)
AMD   68.20 (+0.38%)
T   15.38 (-3.45%)
MU   54.68 (-0.09%)
CGC   3.26 (+6.19%)
F   12.37 (-1.12%)
GE   66.00 (-2.14%)
DIS   100.08 (-0.71%)
AMC   7.22 (-1.50%)
PYPL   94.27 (+0.47%)
PFE   43.12 (-2.27%)
NFLX   240.58 (+1.63%)
S&P 500   3,750.43 (-0.87%)
DOW   29,952.91 (-1.06%)
QQQ   280.02 (-0.70%)
AAPL   145.60 (-0.55%)
MSFT   247.09 (-0.85%)
META   139.51 (+0.38%)
GOOGL   101.49 (+0.06%)
AMZN   120.27 (-0.56%)
TSLA   239.29 (-0.63%)
NVDA   131.52 (-0.43%)
NIO   14.89 (-7.17%)
BABA   84.55 (+0.19%)
AMD   68.20 (+0.38%)
T   15.38 (-3.45%)
MU   54.68 (-0.09%)
CGC   3.26 (+6.19%)
F   12.37 (-1.12%)
GE   66.00 (-2.14%)
DIS   100.08 (-0.71%)
AMC   7.22 (-1.50%)
PYPL   94.27 (+0.47%)
PFE   43.12 (-2.27%)
NFLX   240.58 (+1.63%)
S&P 500   3,750.43 (-0.87%)
DOW   29,952.91 (-1.06%)
QQQ   280.02 (-0.70%)
AAPL   145.60 (-0.55%)
MSFT   247.09 (-0.85%)
META   139.51 (+0.38%)
GOOGL   101.49 (+0.06%)
AMZN   120.27 (-0.56%)
TSLA   239.29 (-0.63%)
NVDA   131.52 (-0.43%)
NIO   14.89 (-7.17%)
BABA   84.55 (+0.19%)
AMD   68.20 (+0.38%)
T   15.38 (-3.45%)
MU   54.68 (-0.09%)
CGC   3.26 (+6.19%)
F   12.37 (-1.12%)
GE   66.00 (-2.14%)
DIS   100.08 (-0.71%)
AMC   7.22 (-1.50%)
PYPL   94.27 (+0.47%)
PFE   43.12 (-2.27%)
NFLX   240.58 (+1.63%)
NASDAQ:AUPH

Aurinia Pharmaceuticals - AUPH Stock Forecast, Price & News

$7.66
+0.11 (+1.46%)
(As of 10/6/2022 03:08 PM ET)
Add
Compare
Today's Range
$7.51
$7.79
50-Day Range
$6.66
$8.63
52-Week Range
$6.28
$33.97
Volume
34,382 shs
Average Volume
2.25 million shs
Market Capitalization
$1.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.75

Aurinia Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
156.2% Upside
$19.75 Price Target
Short Interest
Bearish
8.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of Aurinia Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.85) to ($0.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

897th out of 1,072 stocks

Pharmaceutical Preparations Industry

448th out of 534 stocks

AUPH stock logo

About Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Stock News Headlines

Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc
Why Aurinia Pharmaceuticals Stock Briefly Spiked Today
Why Aurinia Pharmaceuticals Stock Is Plunging
Why Aurinia Pharmaceuticals Stock Perked Up Today
See More Headlines
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Company Calendar

Last Earnings
8/04/2022
Today
10/06/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.75
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+157.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-180,970,000.00
Net Margins
-178.32%
Pretax Margin
-177.46%

Debt

Sales & Book Value

Annual Sales
$45.60 million
Book Value
$3.69 per share

Miscellaneous

Free Float
136,642,000
Market Cap
$1.09 billion
Optionable
Optionable
Beta
0.92

Key Executives

  • Mr. Peter S. Greenleaf M.B.A.Mr. Peter S. Greenleaf M.B.A. (Age 52)
    Pres, CEO & Director
    Comp: $1.24M
  • Mr. Joseph M. Miller CPAMr. Joseph M. Miller CPA (Age 48)
    Chief Financial Officer
    Comp: $710.03k
  • Mr. Matthew Maxwell Donley M.B.A.Mr. Matthew Maxwell Donley M.B.A. (Age 53)
    Exec. VP of Operations & Strategy
    Comp: $730.21k
  • Mr. Stephen P. Robertson (Age 40)
    Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
    Comp: $722.4k
  • Ms. DeDe Sheel
    VP of Investor Relation
  • Mr. Chris Hays
    VP of Marketing
  • Mr. Fran Lynch
    VP of Sales
  • Dr. Robert B. Huizinga M.Sc. (Age 57)
    Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C), Exec. VP of Research
  • Mr. Michael R. Martin (Age 50)
    Chief Bus. Officer
  • Dr. Neil SolomonsDr. Neil Solomons (Age 54)
    Chief Medical Officer













AUPH Stock - Frequently Asked Questions

Should I buy or sell Aurinia Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUPH shares.
View AUPH analyst ratings
or view top-rated stocks.

What is Aurinia Pharmaceuticals' stock price forecast for 2022?

6 Wall Street research analysts have issued 1-year price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price forecasts range from $13.00 to $26.00. On average, they anticipate the company's stock price to reach $19.75 in the next year. This suggests a possible upside of 157.8% from the stock's current price.
View analysts price targets for AUPH
or view top-rated stocks among Wall Street analysts.

How have AUPH shares performed in 2022?

Aurinia Pharmaceuticals' stock was trading at $22.87 at the start of the year. Since then, AUPH shares have decreased by 66.5% and is now trading at $7.66.
View the best growth stocks for 2022 here
.

When is Aurinia Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AUPH earnings forecast
.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.03. The biotechnology company had revenue of $28.19 million for the quarter, compared to the consensus estimate of $27.07 million. Aurinia Pharmaceuticals had a negative net margin of 178.32% and a negative trailing twelve-month return on equity of 38.01%. During the same period last year, the business posted ($0.37) earnings per share.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $7.66.

How much money does Aurinia Pharmaceuticals make?

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.09 billion and generates $45.60 million in revenue each year. The biotechnology company earns $-180,970,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does Aurinia Pharmaceuticals have?

The company employs 300 workers across the globe.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.

This page (NASDAQ:AUPH) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.